Laden…
Etizolam is a thienodiazepine-like sedative with anxiolytic, hypnotic, and muscle-relaxant properties. It primarily acts as an agonist at the GABA-A receptor, leading to enhanced inhibitory neurotransmission in the central nervous system. Due to its pharmacological effects, it is therapeutically used for the treatment of anxiety disorders and sleep disturbances. The risk of dependence and withdrawal symptoms is moderate and should be considered with prolonged use.
Class
Depressiva
Pharmacological context
Mechanism
Etizolam acts as an agonist at the GABA-A receptor, resulting in...
Short read on known pharmacology
Interactions
2 documented
Curated visible combinations
Risk theme
2 high-risk interactions
Condensed from structured notes
Translation in progress
The German version has more complete content. This English page is being expanded; safety-critical risk and interaction sections may still appear while translation continues.
Receptor Targets
Mechanism of Action
Designations
IUPAC: Etizolam
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der GABA-A-Rezeptor ist ein ligandengesteuerter Chloridkanal und der wichtigste inhibitorische Rezeptor im zentralen Nervensystem. Er besitzt multiple allosterische Bindungsstellen für verschiedene Substanzklassen.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class. Limited data — interpret profile with caution.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some details are still being expanded.
Etizolam acts as an agonist at the GABA-A receptor, resulting in enhanced inhibition of neuronal activity. This leads to anxiolytic, sedative, and muscle-relaxant effects.
Reported range 1–2 mg
Total duration 6–8 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 0.5–1 mg |
| Reported | 1–2 mg |
| Strong | 2–3 mg |
Sublingual
| Tier | Dosage |
|---|---|
| Light | 0.5–1 mg |
| Reported | 1–2 mg |
| Strong | 2–3 mg |
Onset
30–60 minutes
Peak
1–2 hours
Total duration
6–8 hours
After effects
2–4 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Mögliche Abhängigkeit und Toleranzentwicklung bei längerem Gebrauch.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Some entries are pharmacological class warnings. They are useful safety signals, but not substance-specific clinical validation.
Some combinations can be dangerous. Research before combining substances. For breathing problems, unconsciousness, seizures, chest pain, high fever, or severe confusion, contact emergency services.
Dangerous interaction risk
Detailed interaction narrative is still being translated. This row shows the available risk level and data provenance only.
Dangerous interaction risk
Detailed interaction narrative is still being translated. This row shows the available risk level and data provenance only.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.